<DOC>
	<DOCNO>NCT00024141</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . PURPOSE : Phase I trial study effectiveness irinotecan follow fluorouracil treat patient advance solid tumor .</brief_summary>
	<brief_title>Irinotecan Followed Fluorouracil Treating Patients With Advanced Solid Tumors</brief_title>
	<detailed_description>OBJECTIVES : - Determine optimal dose irinotecan administer fluorouracil patient advance solid tumor . - Determine toxic effect regimen patient . - Correlate pharmacokinetics irinotecan biologic effect patient . - Assess , preliminary manner , antitumor activity regimen patient . OUTLINE : This dose de-escalation study irinotecan . Patients receive irinotecan IV 90 minute day 1 , 8 , 15 , 22 fluorouracil IV 5 minute day 2 , 9 , 16 , 23 . Treatment repeat every 6 week absence disease progression unacceptable toxicity . Cohorts 6 patient receive decrease dos irinotecan optimal dose determine . The optimal dose define dose least 3 6 patient show evidence recruitment cell S phase 24 hour irinotecan administration . PROJECTED ACCRUAL : A total 18-24 patient accrue study within 12-18 month .</detailed_description>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Camptothecin</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically proven recurrent metastatic solid tumor amenable curative surgery , radiotherapy , conventional chemotherapy proven value Must disease safely readily biopsied local anesthesia ( include , limited , subcutaneous metastasis , superficial lymph node metastasis , ascites ) PATIENT CHARACTERISTICS : Age : 18 Performance status : ECOG 02 Life expectancy : At least 3 month Hematopoietic : WBC least 4,000/mm^3 Platelet count least 100,000/mm^3 Hepatic : Bilirubin great 1.5 time upper limit normal ( ULN ) AST le 2 time ULN Alkaline phosphatase less 2 time ULN Lactic dehydrogenase less 2 time ULN Renal : Creatinine great 1.5 time ULN Other : HIV negative No active uncontrolled bacterial , viral , fungal infection No nonmalignant systemic disease would preclude study participation Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : See Disease Characteristics At least 3 week since prior chemotherapy ( 6 week nitrosoureas mitomycin ) No prior irinotecan Endocrine therapy : Not specify Radiotherapy : See Disease Characteristics At least 4 week since prior radiotherapy except smallport radiotherapy local control No concurrent radiotherapy except smallport radiotherapy local disease control ( e.g. , pain relief impending fracture ) Surgery : See Disease Characteristics At least 2 week since prior major surgery Other : No concurrent anticoagulants except warfarin subcutaneous heparin</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2011</verification_date>
	<keyword>unspecified adult solid tumor , protocol specific</keyword>
</DOC>